Midwest BioResearch, LLC (MBR) Introduces Industry’s First Screen That Fully Predicts the GLP Regulatory Ames Test
3/19/2007 11:58:48 AM
SKOKIE, Ill.--(BUSINESS WIRE)--Midwest BioResearch, LLC (MBR), an outsourced drug disposition and toxicology contract services provider, today announces the introduction of a novel microAmes screen that fully predicts the GLP regulatory Ames test (Salmonella/E. coli Mammalian Microsome Reverse Mutation Assay). The screen is accurate, rapid, flexible and cost-effective, making it an essential consideration for anyone interested in efficient drug discovery and development through smarter decision making during lead optimization.
comments powered by